With several new drug treatments for people with mild COVID-19 now available, it can be tricky to know what your options are should you test positive to COVID-19.
Taskforce directors Steve McGloughlin and Tari Turner, together with Panel co-chairs Bridget Barber and Joshua Davis explain who’s at risk of disease progression, what the treatment options are, and who may benefit most, in this article published in The Conversation today.